Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.71 USD

96.71
547,375

-0.09 (-0.09%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $96.71 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tirthankar Chakraborty headshot

New Strong Buy Stocks for October 29th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.

Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3

by Zacks Equity Research

Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth

by Zacks Equity Research

ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.

Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Align Technology (ALGN) Beats on Earnings and Revenues in Q3

by Zacks Equity Research

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q3.

Will Amedisys' (AMED) Q3 Earnings Reflect Overall Gain?

by Zacks Equity Research

Amedisys' (AMED) Q3 is anticipated to benefit from a strong uptick across all its three business lines consisting of Home Health, Hospice and Personal Care.

LabCorp (LH) Q3 Earnings Lag Estimates, Guidance Tweaked

by Zacks Equity Research

Within LabCorp (LH) Diagnostics business the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth.

Thermo Fisher (TMO) Beats on Q3 Earnings, Ups '18 Guidance

by Zacks Equity Research

Thermo Fisher (TMO) raises its 2018 revenue view, banking on a solid third-quarter operational performance, partially offset by a less favorable foreign exchange.

Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3

by Zacks Equity Research

Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.

Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3

by Zacks Equity Research

Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.

Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues

by Zacks Equity Research

Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.

Top Ranked Growth Stocks to Buy for October 24th

by Zacks Equity Research

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, October 24th:

Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked

by Zacks Equity Research

Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.

PetMed (PETS) Q2 Earnings Grow Y/Y, Reorder Sales Solid

by Zacks Equity Research

PetMed's (PETS) reorder sales growth solid in Q2. Increased online sales buoy optimism.

Amedisys (AMED) Q3 Earnings Preview: What to Watch Ahead of the Release

by Zacks Equity Research

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys to Buy Compassionate Care Hospice, Share Price Down

by Zacks Equity Research

Amedisys (AMED) adopts initiatives to boost hospice business. It expects to become the third-largest hospice provider in America with the latest buyout.

    Quest Diagnostics Boosts Health & Wellness, Acquires Provant

    by Zacks Equity Research

    Quest Diagnostics' (DGX) Provant Health acquisition is in line with its 'accelerate growth' strategy.

    QIAGEN Introduces New RNA-seq Library Preparation Solutions

    by Zacks Equity Research

    QIAGEN (QGEN) adopts initiatives to boost the NGS portfolio.

    Walgreens (WBA) Q4 Earnings Top Estimates, Revenues Lag

    by Zacks Equity Research

    Walgreens' (WBA) Retail Pharmacy USA division witnesses comparable prescription growth and benefits from a strong retail prescription market.

    BioScrip Grows on CORE Plan, Reimbursement Issues Persist

    by Zacks Equity Research

    BioScrip (BIOS) progresses well on the back of its new multi-faceted CORE plan to improve its financial position.

    Genomic Health's Test Gets Favored by New NCCN Guidelines

    by Zacks Equity Research

    Genomic Health (GHDX) forges ahead with the development of Oncotype DX Breast Recurrence Score test.

    Here's Why You Should Invest in Boston Scientific Stock Now

    by Zacks Equity Research

    Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.

    Edwards Begins US CENTERA Study, Reintroduces Valve in Europe

    by Zacks Equity Research

    Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.

    Here's Why You Should Invest in Genomic Health (GHDX) Now

    by Zacks Equity Research

    Genomic Health (GHDX) continues to see increasing private coverage for the Oncotype DX GPS test.